4. (Amended) Peptide compounds of the formula I according to Claim 1 and the compounds selected from the group consisting of

cyclo (Arg-Gly-Asp-Leu-Asp-Ala-Leu-Arg-Gly-Gly-Gly),

cyclo (Arg-Gly-Asp-Leu-Asp-Gly-Leu-Arg-Gly-Leu-Arg-Gly-Gly-Gly),

cyclo (Arg-Gly-Asp-Leu-D-Ala-Ala-Leu-Arg-Gly-Gly-Gly),

cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Gly-Gly-Gly),

cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),

cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha-Aha),

cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha),

cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aee),

cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),

cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg- β-Ala),

cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg- β-Ala),

and their physiologically acceptable salts and solvates, as medicaments.

7. (Amended) Pharmaceutical preparation, comprising at least one medicament according to Claim 5 and, if appropriate, vehicles and/or excipients and, if appropriate, other active compounds.

8. (Amended) Use of peptide compounds according to Claim 1 and/or their physiologically acceptable salts for producing a medicament for the control of disorders which are based on expression and pathological function of $\alpha_v\beta_6$ integrin receptors.

REMARKS